Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorAlzheimer's Light LLC

About this trial

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.

Eligibility criteria

Qualifiers

Alzheimer's disease

Cognitive Impairment

Disqualifiers

any previously noted epileptic seizures, including febrile seizures.

any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.

Trial design

Treatments tested in this trial

  • Combination of 40Hz light and cognitive therapy (ALZLIFE)

Treatment groups

2,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators